Clinical trial
A Phase 2, Randomized, Dose-Ranging, Single-Blind, Efficacy and Tolerability Study of ILY101 in Patients With Chronic Kidney Disease With Hyperphosphatemia on Hemodialysis
NCT00358046 is registered in ClinicalTrials.gov with Ilypsa as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Dose-Ranging, Single-Blind, Efficacy and Tolerability Study of ILY101 in Patients With Chronic Kidney Disease With Hyperphosphatemia on Hemodialysis
- Lead sponsor
- Ilypsa
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2006
- Completion date
- Not reported
- Enrollment
- 120
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.